8-K: Axsome Therapeutics Settles Sunosi Patent Litigation with Hikma Pharmaceuticals USA

Axsome Therapeutics has reached a settlement agreement with Hikma Pharmaceuticals USA, resolving patent litigation concerning Axsome's Sunosi (solriamfetol) product.

Summary

• Axsome Therapeutics has settled its patent litigation with Hikma Pharmaceuticals USA regarding Sunosi (solriamfetol).
• Hikma submitted an Abbreviated New Drug Application to the FDA seeking approval to market a generic version of Sunosi in the United States, leading to the litigation.
• Under the settlement, Axsome will grant Hikma a license to sell its generic Sunosi on or after September 1, 2040, if pediatric exclusivity is granted, or on or after March 1, 2040, if not.
• The agreement is subject to FDA approval and customary conditions.
• Similar patent litigation against other parties related to Sunosi remains pending.
• The settlement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

Sentiment

Score: 6

Explanation: The settlement removes uncertainty but allows for generic competition in the long term. The sentiment is neutral to slightly positive.

Positives

• The settlement provides clarity on the patent protection timeline for Sunosi.
• Axsome retains market exclusivity for Sunosi until at least 2040.
• Resolving the litigation with Hikma removes a potential overhang for Axsome.

Negatives

• The settlement allows for a generic version of Sunosi to enter the market in 2040, potentially impacting future revenue.
• Axsome still faces ongoing patent litigation with other parties regarding Sunosi.

Risks

• The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, and may not be approved.
• Ongoing patent litigation with other parties could result in further settlements or unfavorable outcomes for Axsome.
• The commercial success of Sunosi, Auvelity, and Symbravo products is subject to risks and uncertainties.
• The company's ability to obtain additional indications with respect to solriamfetol and/or AXS-05 is not guaranteed.
• The company's ability to maintain and expand payer coverage is subject to risks and uncertainties.

Future Outlook

The company's future results are subject to risks and uncertainties, including the commercial success of its products, the outcome of clinical trials, regulatory approvals, intellectual property disputes, and market acceptance.

Industry Context

This settlement is part of the ongoing landscape of pharmaceutical companies protecting their intellectual property through patent litigation, particularly against generic drug manufacturers seeking to enter the market with lower-cost alternatives. Settlements like these are common and often involve licensing agreements that allow generic entry at a later date.

Comparison to Industry Standards

• Patent settlements in the pharmaceutical industry are common, with companies like Teva Pharmaceuticals, Mylan (now Viatris), and Novartis often involved in similar litigation and settlements.
• The timing of generic entry (2040) is relatively far out, suggesting Axsome has strong patent protection for Sunosi.
• Comparable settlements often involve tiered royalty payments to the innovator company, but this detail is not disclosed in this announcement.

Legal Proceedings

• Axsome is involved in patent litigation with Hikma Pharmaceuticals USA related to Sunosi (solriamfetol).
• Similar patent litigation brought by Axsome against other parties related to Sunosi remains pending in the U.S. District Court for the District of New Jersey.

Stakeholder Impact

• Shareholders: The settlement provides clarity on the future market exclusivity of Sunosi.
• Patients: The settlement ensures continued access to Sunosi while also paving the way for a generic alternative in the future.
• Hikma: The settlement grants Hikma a license to sell a generic version of Sunosi starting in 2040.

Next Steps

• Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
• Axsome will continue to pursue patent litigation against other parties related to Sunosi.

Key Dates